Zoetis Products Earn Top Honors in 2016 Animal Pharm Awards

Zoetis recently won two awards for industry-leading innovation in the 2016 Animal Pharm Awards competition. Animal Pharm, the most widely read newsletter reporting on the animal health industry, announced the award winners on January 17.

Zoetis was recognized with top honors in the categories of Best New Product – Companion Animal for the monoclonal antibody therapy CYTOPOINT™ and Best New Product Portfolio for a portfolio of new canine products launched in 2016, including CYTOPOINT™, Simparica® (sarolaner) and VANGUARD® vaccines.

Animal Pharm's annual industry awards are designed to honor achievements within the animal health sector over the calendar year. Subscribers can nominate companies, products and employees in 12 award categories. A panel of judges comprised of industry experts evaluate the nominations and select the winners. 

​Award-winning products

Zoetis' wins in the Best New Product categories speak to the high caliber of the company's research and development program.

Winning Best New Product – Companion Animal, CYTOPOINT™ was developed by Zoetis scientists as the first caninized monoclonal antibody licensed in the United States to help reduce clinical signs such as itching associated with atopic dermatitis in dogs of any age. It neutralizes interleukin – 31 (IL - 31), a protein responsible for triggering itch in dogs. Zoetis scientists confirmed the role of IL-31 in canine atopic dermatitis. The idea that targeting and neutralizing IL-31 with an antibody approach, spurred the design and development of this unique, caninized antibody. 

Zoetis also received the Best New Product Portfolio Award for its new group of companion animal products developed by Zoetis scientists and launched in 2016:

• CYTOPOINT™, the first-of-its kind anti-canine IL-31 monoclonal antibody licensed to help reduce clinical signs such as itching associated with atopic dermatitis in dogs
• Simparica^®​  (sarolaner), Zoetis' chewable flea and tick medication for dogs that offers persistent month-long efficacy for 35 days
• Multiple vaccine products in the VANGUARD^®​​  franchise - VANGUARD B oral, VANGUARD Rapid Resp and Vanguard crLyme

According to Animal Pharm editors, "The judges were impressed with the innovative and game-changing nature of the additions to the Zoetis portfolio in 2016.​”

"We are proud of these and all the breakthrough products our team develops to advance animal health throughout the world," said Cathy Knupp, Executive Vice President and President, Research and Development at Zoetis. "Our colleagues are passionate about the work we do, and they continue to make a huge difference in helping address the real-world challenges of veterinarians and livestock producers who raise and care for animals."

Read more about the 2016 Animal Pharm Awards here.